Early ADHD Medication May Reduce Risk of Psychotic Disorders in Adulthood
A large-scale study has found that treating ADHD with stimulant medications during childhood may lower the risk of severe psychotic disorders in later life. Researchers analysed data from nearly 700,000 individuals in Finland, uncovering a potential long-term benefit of early intervention. The study, led by Professor Ian Kelleher from University College Dublin and the University of Edinburgh, was published in JAMA Psychiatry. It used advanced statistical techniques to adjust for regional differences in prescribing habits. The findings showed that children who received stimulant treatment for ADHD—particularly before age 13—had a reduced risk of developing conditions like schizophrenia in adulthood.
The research also confirmed that methylphenidate, a common ADHD medication, did not increase the likelihood of psychotic disorders later in life. Dr. Colm Healy, the lead author, stressed the importance of early diagnosis and evidence-based treatment for ADHD. He highlighted that thorough clinical assessments could help maximise the benefits of medication while minimising risks. Over the past decade, global medical guidelines have increasingly supported the safety of methylphenidate. Long-term studies, including a 2023 *Lancet Psychiatry* report, found no links to growth disorders or serious psychiatric side effects in children. The World Health Organization has faced calls to reconsider its essential medicines list, while European consensus now recommends stimulants as a first-line treatment for children and a second-line option for adults. Meta-analyses up to 2025 have shown sustained efficacy without tolerance issues.
The study offers reassurance to families and clinicians about the long-term safety of ADHD medications. Early stimulant treatment, when carefully managed, may provide lasting protection against severe mental illness. Researchers hope these findings will encourage more timely and evidence-based interventions for children with ADHD.
